Oxford Ledge
Search
No licensed closing price on file for LRMR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:12 UTC.
We are a clinical-stage biotechnology company developing treatments for rare diseases using a cell penetrating peptide technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered fusion protein designed to deliver frataxin protein to patients with Friedreich's ataxia, a rare progressive disease caused by insufficient frataxin production. Currently, no therapies address the core deficiency in Friedreich's ataxia, making nomlabofusp the first potential therapy designed to systemically increase frataxin levels in affected patients.
Summarized from Larimar Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | 3,333.14% |
We are a clinical-stage biotechnology company developing treatments for rare diseases using a cell penetrating peptide technology platform.
Larimar Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:12 UTC. This page is also available as JSON at /api/data?ticker=LRMR and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for LRMR and 5,000+ tickers.
Create a free account — keep LRMRGET /api/data?ticker=LRMR
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt